Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer

Cancer Treatment Reviews

Volumn 37, Issue 5, 2011, Pages 331-343

  van Loon, Judith ^a   van Baardwijk, Angela ^a   Boersma, Liesbeth ^a   Öllers, Michel ^a   Lambin, Philippe ^a   De Ruysscher, Dirk ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Combined modality treatment; Lung cancer; Molecular imaging; NSCLC; PET; Radiotherapy; SCLC

Indexed keywords

ATELECTASIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; EXPOSURE; FOLLOW UP; FUTUROLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; IRRADIATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79957500028     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.01.005     Document Type: Review

References (180)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Auperin A., Le Pechoux C., Rolland E., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-2190.
3. Janssen-Heijnen M.L., Coebergh J.W. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001, 31:123-137.
4. Jett J.R., Schild S.E., Keith R.L., Kesler K.A. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:266S-276S.
5. Hoekstra C.J., Stroobants S.G., Hoekstra O.S., et al. The value of [18F]fluoro-2-deoxy-d-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003, 39:151-157.
6. Mac Manus M.P., Hicks R.J., Ball D.L., et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001, 92:886-895.
7. Mac Manus M.P., Wong K., Hicks R.J., Matthews J.P., Wirth A., Ball D.L. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 2002, 52:351-361.
8. Hicks R.J., Kalff V., MacManus M.P., et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001, 42:1596-1604.
9. MacManus M.P., Hicks R.J., Matthews J.P., et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001, 50:287-293.
10. Nestle U., Weber W., Hentschel M., Grosu A.L. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol 2009, 54:R1-R25.
11. Van de Steene J., Linthout N., de Mey J., et al. Definition of gross tumor volume in lung cancer: inter-observer variability. Radiother Oncol 2002, 62:37-49.
12. Steenbakkers R.J., Duppen J.C., Fitton I., et al. Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a 'Big Brother' evaluation. Radiother Oncol 2005, 77:182-190.
13. Mah K., Caldwell C.B., Ung Y.C., et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002, 52:339-350.
14. Steenbakkers R.J., Duppen J.C., Fitton I., et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys 2006, 64:435-448.
15. Ashamalla H., Rafla S., Parikh K., et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005, 63:1016-1023.
16. Fox J.L., Rengan R., O'Meara W., et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?. Int J Radiat Oncol Biol Phys 2005, 62:70-75.
17. Bradley J., Thorstad W.L., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 59:78-86.
18. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999, 44:593-597.
19. Lowe V.J., Fletcher J.W., Gobar L., et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998, 16:1075-1084.
20. Nestle U., Kremp S., Grosu A.L. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 2006, 81:209-225.
21. Geets X., Lee J.A., Bol A., Lonneux M., Gregoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging 2007, 34:1427-1438.
22. Black Q.C., Grills I.S., Kestin L.L., et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 2004, 60:1272-1282.
23. Daisne J.F., Sibomana M., Bol A., Doumont T., Lonneux M., Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol 2003, 69:247-250.
24. Nestle U., Kremp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med 2005, 46:1342-1348.
25. Macmanus M.P., Hicks R.J. Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography. Int J Radiat Oncol Biol Phys 2008, 71:2-4.
26. Bayne M., Hicks R.J., Everitt S., et al. Reproducibility of " intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. Int J Radiat Oncol Biol Phys 2010, 77:1151-1157.
27. Wu K., Ung Y.C., Hornby J., et al. PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings?. Int J Radiat Oncol Biol Phys. 2009.
28. Yu H.M., Liu Y.F., Hou M., Liu J., Li X.N., Evaluation Yu.J.M., et al. 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur J Radiol 2009, 72:104-113.
29. van Baardwijk A., Bosmans G., Boersma L., et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007, 68:771-778.
30. Dahele M., Hwang D., Peressotti C., et al. Developing a methodology for three-dimensional correlation of PET-CT images and whole-mount histopathology in non-small-cell lung cancer. Curr Oncol 2008, 15:62-69.
31. Stroom J., Blaauwgeers H., van Baardwijk A., et al. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys 2007, 69:267-275.
32. Siedschlag C., van Loon J., van Baardwijk A., et al. Analysis of the relative deformation of lung lobes before and after surgery in patients with NSCLC. Phys Med Biol 2009, 54:5483-5492.
33. Cooper R.A., Carrington B.M., Loncaster J.A., et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000, 57:53-59.
34. Foo S.S., Abbott D.F., Lawrentschuk N., Scott A.M. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 2004, 6:291-305.
35. Zhao S., Kuge Y., Mochizuki T., et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005, 46:675-682.
36. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005, 6:112-117.
37. Bentzen S.M. Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treat Res 2008, 139:41-62.
38. Galvin J.M., De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol 2007, 25:924-930.
39. Das S.K., Miften M.M., Zhou S., et al. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys 2004, 31:1452-1461.
40. Aerts H.J., van Baardwijk A.A., Petit S.F., et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009, 91:386-392.
41. Abramyuk A., Tokalov S., Zophel K., et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?. Radiother Oncol 2009, 91:399-404.
42. Aerts H.J., Bosmans G., van Baardwijk A.A., et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys 2008, 71:1402-1407.
43. Christensen J.D., Colby T.V., Patz E.F. Correlation of [18F]-2-fluoro-deoxy-d-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. Cancer 2010, 116:4095-4102.
44. Caldwell C.B., Mah K., Skinner M., Danjoux C.E. Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET. Int J Radiat Oncol Biol Phys 2003, 55:1381-1393.
45. Nehmeh S.A., Erdi Y.E. Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med 2008, 38:167-176.
46. Grgic A., Nestle U., Schaefer-Schuler A., Kremp S., Kirsch C.M., Hellwig D. FDG-PET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning-an intraindividual comparison. Int J Radiat Oncol Biol Phys 2009, 73:103-111.
47. Chan R., He Y., Haque A., Zwischenberger J. Computed tomographic-pathologic correlation of gross tumor volume and clinical target volume in non-small cell lung cancer: a pilot experience. Arch Pathol Lab Med 2001, 125:1469-1472.
48. Giraud P., Antoine M., Larrouy A., et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000, 48:1015-1024.
49. Grills I.S., Fitch D.L., Goldstein N.S., et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys 2007, 69:334-341.
50. Belderbos J.S., Kepka L., Spring Kong F.M., Martel M.K., Videtic G.M., Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small-Cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008, 72:335-342.
51. Senan S., De Ruysscher D., Giraud P., Mirimanoff R., Budach V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004, 71:139-146.
52. Gould M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003, 139:879-892.
53. Senan S., Burgers S., Samson M.J., et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 2002, 54:999-1006.
54. Belderbos J.S., Heemsbergen W.D., De Jaeger K., Baas P., Lebesque J.V. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66:126-134.
55. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2005, 62:988-994.
56. Sulman E.P., Komaki R., Klopp A.H., Cox J.D., Chang J.Y. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 2009, 4:5.
57. Sura S., Greco C., Gelblum D., Yorke E.D., Jackson A., Rosenzweig K.E. (18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:1397-1402.
58. De Ruysscher D., Wanders S., Minken A., et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 2005, 77:5-10.
59. van Der Wel A., Nijsten S., Hochstenbag M., et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys 2005, 61:649-655.
60. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000, 55:317-324.
61. Gomez-Caro A, Garcia S, Reguart N, et al. Incidence of occult mediastinal node involvement in CN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. Eur J Cardiothorac Surg.
62. Zhao L., Chen M., Ten Haken R., et al. Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 2007, 82:153-159.
63. Nestle U., Schaefer-Schuler A., Kremp S., et al. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007, 34:453-462.
64. Thomas J.G., Kashani R., Balter J.M., Tatro D., Kong F.M., Pan C.C. Intra and interfraction mediastinal nodal region motion: implications for internal target volume expansions. Med Dosim 2009, 34:133-139.
65. Bosmans G., van Baardwijk A., Dekker A., et al. Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 71:139-144.
66. Pantarotto J.R., Piet A.H., Vincent A., de Koste J.R., Senan S. Motion analysis of 100 mediastinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies. Int J Radiat Oncol Biol Phys 2009, 74:1092-1099.
67. van Baardwijk A., Bosmans G., Boersma L., et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 2008, 71:1394-1401.
68. van Baardwijk A., Wanders S., Boersma L., et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010, 28(8):1380-1386.
69. Feng M., Kong F.M., Gross M., Fernando S., Hayman J.A., Ten Haken R.K. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys 2009, 73:1228-1234.
70. Gillham C., Zips D., Ponisch F., et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol 2008, 88:335-341.
71. Petit S.F., Aerts H.J., van Loon J.G., et al. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study. Radiother Oncol 2009, 91:393-398.
72. Rasey J.S., Koh W.J., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36:417-428.
73. Thorwarth D., Eschmann S.M., Scheiderbauer J., Paulsen F., Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005, 5:152.
74. Mees G., Dierckx R., Vangestel C., Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009, 36:1674-1686.
75. Sovik A., Malinen E., Skogmo H.K., Bentzen S.M., Bruland O.S., Olsen D.R. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys 2007, 68:1496-1504.
76. Everitt S., Hicks R.J., Ball D., et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009, 75:1098-1104.
77. Ataman O.U., Barrett A., Filleron T., Kramar A. Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTRO. Radiother Oncol 2006, 78:95-100.
78. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
79. Mac Manus M.P., Hicks R.J., Matthews J.P., Wirth A., Rischin D., Ball D.L. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005, 49:95-108.
80. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46:87-98.
81. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005, 23:5910-5917.
82. Korst R.J., Gold H.T., Kent M.S., Port J.L., Lee P.C., Altorki N.K. Surveillance computed tomography after complete resection for non-small cell lung cancer: results and costs. J Thorac Cardiovasc Surg 2005, 129:652-660.
83. Korst R.J., Kansler A.L., Port J.L., Lee P.C., Altorki N.K. Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. Ann Thorac Surg 2006, 82:1009-1015. discussion 15.
84. Higashi K., Ueda Y., Ayabe K., et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000, 21:707-714.
85. Higashi K., Ueda Y., Yagishita M., et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000, 41:85-92.
86. Vesselle H., Schmidt R.A., Pugsley J.M., et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000, 6:3837-3844.
87. Berghmans T., Dusart M., Paesmans M., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008, 3:6-12.
88. Ichiya Y., Kuwabara Y., Sasaki M., et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 1996, 10:193-200.
89. Eschmann S.M., Friedel G., Paulsen F., et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?. Eur J Nucl Med Mol Imaging 2006, 33:263-269.
90. Borst G.R., Belderbos J.S., Boellaard R., et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005, 41:1533-1541.
91. Hoang J.K., Hoagland L.F., Coleman R.E., Coan A.D., Herndon J.E., Patz E.F. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008, 26:1459-1464.
92. Higashi K., Clavo A.C., Wahl R.L. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993, 34:414-419.
93. van Baardwijk A., Dooms C., van Suylen R.J., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007, 43:1392-1398.
94. Nahmias C., Hanna W.T., Wahl L.M., Long M.J., Hubner K.F., Townsend D.W. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 2007, 48:744-751.
95. Hoekstra C.J., Stroobants S.G., Smit E.F., et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:8362-8370.
96. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21:2651-2657.
97. de Geus-Oei L.F., van der Heijden H.F., Visser E.P., et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007, 48:1592-1598.
98. Decoster L., Schallier D., Everaert H., et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2008, 62:55-61.
99. Hellwig D., Graeter T.P., Ukena D., Georg T., Kirsch C.M., Schafers H.J. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004, 128:892-899.
100. Pottgen C., Levegrun S., Theegarten D., et al. Value of 18F-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006, 12:97-106.
101. Tanvetyanon T., Eikman E.A., Sommers E., Robinson L., Boulware D., Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol 2008, 26:4610-4616.
102. Kong F.M., Frey K.A., Quint L.E., et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007, 25:3116-3123.
103. Zhang HQ, Yu JM, Meng X, Yue JB, Feng R, Ma L. Prognostic value of serial [(18)F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy. Eur J Radiol 2009 Aug 18. Epub ahead of print.
104. van Baardwijk A., Bosmans G., Dekker A., et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 2007, 82:145-152.
105. Krak N.C., Boellaard R., Hoekstra O.S., Twisk J.W., Hoekstra C.J., Lammertsma A.A. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005, 32:294-301.
106. Minn H., Zasadny K.R., Quint L.E., Wahl R.L. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology 1995, 196:167-173.
107. Nakamoto Y., Zasadny K.R., Minn H., Wahl R.L. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol 2002, 4:171-178.
108. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
109. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003, 21:1285-1292.
110. Wahl R.L., Jacene H., Kasamon Y., From Lodge.M.A., ST R.E.C.I. To PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122S-150S.
111. Bruzzi J.F., Munden R.F. PET/CT imaging of lung cancer. J Thorac Imaging 2006, 21:123-136.
112. Hicks R.J., Kalff V., MacManus M.P., et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001, 42:1605-1613.
113. Rubins J., Unger M., Colice G.L. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 2007, 132:355S-367S.
114. Duhaylongsod F.G., Lowe V.J., Patz E.F., Vaughn A.L., Coleman R.E., Wolfe W.G. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995, 110:130-139. discussion 9-40.
115. Patz E.F., Lowe V.J., Hoffman J.M., Paine S.S., Harris L.K., Goodman P.C. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-d-glucose. Radiology 1994, 191:379-382.
116. Hebert M.E., Lowe V.J., Hoffman J.M., Patz E.F., Anscher M.S. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996, 19:416-421.
117. Choi N.C., Herndon J.E., Rosenman J., et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998, 16:3528-3536.
118. Eschmann S.M., Friedel G., Paulsen F., et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007, 34:463-471.
119. Ryu J.S., Choi N.C., Fischman A.J., Lynch T.J., Mathisen D.J. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002, 35:179-187.
120. Keidar Z., Haim N., Guralnik L., et al. PET/CT using 18F-FDG in suspected lung cancer recurrence. Diagnostic value and impact on patient management. J Nucl Med 2004, 45:1640-1646.
121. Hicks R.J., Mac Manus M.P., Matthews J.P., et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004, 60:412-418.
122. Henderson M.A., Hoopes D.J., Fletcher J.W., et al. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:789-795.
123. Ishimori T., Saga T., Nagata Y., et al. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med 2004, 18:669-674.
124. Benamore R., Shepherd F.A., Leighl N., et al. Does intensive follow-up alter outcome in patients with advanced lung cancer?. J Thorac Oncol 2007, 2:273-281.
125. Edelman M.J., Schuetz J. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection. Curr Treat Options Oncol 2002, 3:67-73.
126. Walsh G.L., O'Connor M., Willis K.M., et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. Ann Thorac Surg 1995, 60:1563-1570. discussion 70-2.
127. Patz E.F., Connolly J., Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 2000, 174:769-774.
128. Ahuja V., Coleman R.E., Herndon J., Patz E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998, 83:918-924.
129. Downey R.J., Akhurst T., Gonen M., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004, 22:3255-3260.
130. Kased N., Erasmus J.J., Komaki R., Cox J.D. Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review. J Thorac Oncol 2008, 3:534-538.
131. van Loon J., Grutters J., Wanders R., et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer 2009, 45:588-595.
132. van Loon J., Grutters J.P., Wanders R., et al. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation. Eur J Cancer 2010, 46:110-119.
133. Apisarnthanarax S., Alauddin M.M., Mourtada F., et al. Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 2006, 12:4590-4597.
134. Buck A.K., Halter G., Schirrmeister H., et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003, 44:1426-1431.
135. Muzi M., Vesselle H., Grierson J.R., et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005, 46:274-282.
136. Wagner M., Seitz U., Buck A., et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003, 63:2681-2687.
137. Yamamoto Y., Nishiyama Y., Ishikawa S., et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007, 34:1610-1616.
138. Yap C.S., Czernin J., Fishbein M.C., et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006, 129:393-401.
139. Pan M.H., Huang S.C., Liao Y.P., et al. FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol 2008, 10:325-334.
140. Roels S., Slagmolen P., Nuyts J., et al. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?. Acta Oncol 2008, 47:1237-1248.
141. Wieder H.A., Geinitz H., Rosenberg R., et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007, 34:878-883.
142. Kubota R., Kubota K., Yamada S., et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995, 36:484-492.
143. Nettelbladt O.S., Sundin A.E., Valind S.O., et al. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 1998, 39:640-647.
144. Tsuyuguchi N., Sunada I., Ohata K., et al. Evaluation of treatment effects in brain abscess with positron emission tomography: comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine. Ann Nucl Med 2003, 17:47-51.
145. van Waarde A., Jager P.L., Ishiwata K., Dierckx R.A., Elsinga P.H. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006, 47:150-154.
146. Murayama C., Harada N., Kakiuchi T., et al. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med 2009, 50:290-295.
147. Yamaura G., Yoshioka T., Fukuda H., et al. O-[18F]fluoromethyl-l-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine. Eur J Nucl Med Mol Imaging 2006, 33:1134-1139.
148. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep. 1973, 4:31-42. Part 3.
149. de Jong W.K., Schaapveld M., Blaauwgeers J.L., Groen H.J. Pulmonary tumours in the Netherlands: focus on temporal trends in histology and stage and on rare tumours. Thorax 2008, 63:1096-1102.
150. Bunn P.A., Carney D.N. Overview of chemotherapy for small cell lung cancer. Semin Oncol 1997, 24. S7-69-S7-74.
151. Ihde D.C. Small cell lung cancer. State-of-the-art therapy 1994. Chest 1995, 107:243S-248S.
152. Bradley J.D., Dehdashti F., Mintun M.A., Govindan R., Trinkaus K., Siegel B.A. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004, 22:3248-3254.
153. Brink I., Schumacher T., Mix M., et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004, 31:1614-1620.
154. Chin R., McCain T.W., Miller A.A., et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002, 37:1-6.
155. Fischer B.M., Mortensen J., Langer S.W., et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007, 18:338-345.
156. Niho S., Fujii H., Murakami K., et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007, 57:328-333.
157. Pandit N., Gonen M., Krug L., Larson S.M. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003, 30:78-84.
158. Shen Y.Y., Shiau Y.C., Wang J.J., Ho S.T., Kao C.H. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 2002, 22:1257-1264.
159. Vinjamuri M., Craig M., Campbell-Fontaine A., Almubarak M., Gupta N., Rogers J.S. Can positron emission tomography be used as a staging tool for small-cell lung cancer?. Clin Lung Cancer 2008, 9:30-34.
160. Ung Y.C., Maziak D.E., Vanderveen J.A., et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007, 99:1753-1767.
161. Azad A., Chionh F., Scott A.M., et al. High Impact of (18)F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol 2009, 12(4):443-451.
162. Blum R., MacManus M.P., Rischin D., Michael M., Ball D., Hicks R.J. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 2004, 27:164-171.
163. Kamel E.M., Zwahlen D., Wyss M.T., Stumpe K.D., von Schulthess G.K., Steinert H.C. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003, 44:1911-1917.
164. Schumacher T., Brink I., Mix M., et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001, 28:483-488.
165. Videtic G.M., Belderbos J.S., Spring Kong F.M., Kepka L., Martel M.K., Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 2008, 72:327-334.
166. De Ruysscher D., Bremer R.H., Koppe F., et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol 2006, 80:307-312.
167. van Loon J., Offermann C., Bosmans G., et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol 2008, 87:49-54.
168. Turrisi A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265-271.
169. Vanloon J., De Ruysscher D., Wanders R., et al. Selective Nodal Irradiation on Basis of (18)FDG-PET Scans in Limited-Disease Small-Cell Lung Cancer: A Prospective Study. Int J Radiat Oncol Biol Phys 2010, 77(2):329-336. Part 1.
170. De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006, 24:1057-1063.
171. De Ruysscher D., Pijls-Johannesma M., Vansteenkiste J., Kester A., Rutten I., Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006, 17:543-552.
172. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005:CD004700.
173. Jeremic B., Shibamoto Y., Nikolic N., et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999, 17:2092-2099.
174. Shepherd F.A., Ginsberg R.J., Haddad R., et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 1993, 11:1592-1597.
175. Shepherd F.A., Crowley J., Van Houtte P., et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007, 2:1067-1077.
176. Vallieres E., Shepherd F.A., Crowley J., et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009, 4:1049-1059.
177. Lee Y.J., Cho A., Cho B.C., et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 2009, 15:2426-2432.
178. Fischer B.M., Mortensen J., Langer S.W., et al. PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer 2006, 54:41-49.
179. Yamamoto Y., Kameyama R., Murota M., Bandoh S., Ishii T., Nishiyama Y. Early assessment of therapeutic response using FDG PET in small cell lung cancer. Mol Imaging Biol 2009, 11:467-472.
180. Onitilo A.A., Engel J.M., Demos J.M., Mukesh B. Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer. Clin Med Res 2008, 6:72-77.